Answer
Seretide Accuhaler 50/500 micrograms is indicated for symptomatic treatment of patients with COPD whose pre-bronchodilator FEV1 is below 60% of predicted normal, who have a history of repeated exacerbations and significant symptoms despite regular bronchodilator therapy.
Sources for this answer
- Seretide 100, 250, 500 AccuhalerGlaxoSmithKline UK · emc · SmPC §4.1 Therapeutic Indications · Version 46Document updated
Sources checked